27 March 2026 | News
Image Courtesy: Public Domain
CMR Surgical announced that more than 45,000 patients worldwide have now been treated using the Versius® Surgical Robotic System, marking a major milestone for the Cambridge, U.K.-based surgical robotics company as it prepares to expand into the United States. The milestone reflects sustained multi–specialty clinical adoption of Versius, positioning CMR as the second most widely used robotic surgery platform globally.
The company announced the milestone at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2026 Annual Meeting in Tampa. CMR is launching Versius in the U.S. following FDA clearance of the next-generation Versius Plus system in December 2025 for cholecystectomy (gallbladder removal).
The conference marks what company leaders describe as CMR’s formal introduction to U.S. surgeons, as it begins building partnerships with hospitals and ambulatory surgery centers (ASCs) ahead of a broader rollout.
“This milestone is twofold and reflects the growing global momentum behind Versius and the confidence surgeons have in the platform,” said Massimiliano Colella, Chief Executive Officer of CMR Surgical. “But equally important, it comes at a watershed moment for CMR as we introduce Versius Plus to the U.S. surgical community and begin expanding access to our technology in the world’s largest robotic surgery market.”
Versius has been adopted in hospitals across more than 30 countries, supporting procedures including general surgery, colorectal surgery, urology, gynecology and thoracic surgery. CMR is differentiated by its established global adoption, proven clinical use and extensive real-world data. CMR is now focused on establishing a foothold in the U.S.
"This is a pivotal moment for CMR,” said Chris O’Hara, President and General Manager, U.S. “Versius Plus was designed to meet the practical realities of today’s healthcare environment; adaptable across operating rooms, efficient to integrate into existing surgical programs, and scalable for long-term growth. With FDA clearance now in place and additional indications planned, we are focused on partnering with forward-thinking health systems to expand the role of robotic-assisted surgery across specialties and care settings.”
Unlike traditional systems fixed in a single operating room, Versius features a modular design with independent robotic arms that can be positioned around the patient and efficiently moved between operating rooms, enabling broader use across surgical departments.
“In surgical robotics, what ultimately matters is how a system performs in real clinical environments over time,” said Dr. Francesco Bianco, Division of General, Minimally Invasive & Robotic Surgery, University of Illinois Chicago. “What’s notable here is the scale of experience behind Versius, with tens of thousands of procedures contributing to a growing body of clinical understanding. That level of real-world use, and the data that come with it, is important as surgeons evaluate new technologies entering the U.S. market.”
